True Religion Apparel Inc.‘s (NASDAQ:TRLG) Q2 is coming along well, says Benchmark Co., as its spring/summer line received good reviews. Benchmark holds to a Buy rating on the stock and a $38 price target.
Teavana Holdings, Inc. (NYSE:TEA): There is a definite difference between Starbucks’ (NASDAQ:SBUX) coming debut of its Tazo Tea store and Teavana, according to William Blair. The firm doesn’t see Starbucks’ plans as an imminent drawback for Teavana, and still thinks the Teavana concept will be a reliable growth vehicle. It repeats its Outperform rating on the company.
Onyx Pharmaceuticals Inc.‘s (NASDAQ:ONXX) price target has been raised by JPMorgan following a vote by the FDA’s Oncologic Drugs Advisory Committee in favor of sped-up approval of Kyprolis. JPMorgan maintains an Overweight rating on the stock.
Bed Bath & Beyond, Inc. (NASDAQ:BBBY) announced higher than planned EPS but lower than planned comparative sales, leading Bernstein to believe its results might beat expectations in the future. Bernstein thinks the stock will be attractive in a shaky economic environment and sticks to an Outperform rating.
Celgene Corporation‘s (NASDAQ:CELG) Revlimid will in due time be approved by the E.U., Bernstein believes, so is sticking to an Outperform rating on the stock.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.